Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world.
Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 62 NGS-related patents, as well as nearly 20,000 SCI articles with a total impact factor of nearly 120,000, including publications in first tiers journals such as Cell, Nature and Science.
As the largest NGS service provider headquartered in Beijing with branches in Hong Kong China, US, UK, Singapore, Netherlands, and Japan, Novogene was founded in 2011 and has been growing rapidly over the past few years. Novogene has genomic sequencing labs in the US (at The University of California at Davis campus), China, Singapore, and the UK (Cambridge).
Company founder, Dr. Ruiqiang Li
Dr. Ruiqiang Li has been engaged in bioinformatics and genomics research for over a decade, developing a series of next-generation sequencing data analysis methods and software. He has participated in or led many genome research projects and published more than 100 research papers on his work, which have been cited more than 55,000 times. His publications include 38 articles in Science, Nature, and their affiliated journals. From 2014 to 2022, Dr. Li was among the top-citied Chinese authors. He has also applied for 35 invention patents.
Obtained Practice License of Medical institution for Guangzhou Novogene Med LAB2023
Established Guangzhou Novogene Med LAB
The self-developed Falcon II platform is deployed globally2022
Novogene (stock code: 688315) officially launched into SSE STAR Market.
Cambridge Sequencing Center obtained ISO/IEC 17025 accreditation and launched European Clinical Services2021
Launched Falcon, our world-leading intelligent NGS delivery platform, to significantly improve the efficiency, reliability and quality of production.
Fought against COVID-19 pandemic and supported large-scale nucleic acid testing in Beijing, Qingdao, Tianjin, Chengdu and other places to assume social responsibility.2020
Established Novogene Netherlands B.V. and Novogene Japan k.k.2019
Received CFDA Approval for NovoFocus NSCLC CDx Test.
Obtained CLIA certification for the UC Davis Sequencing Center.
Established the Cambridge Sequencing Center.2018
Obtained the first CAP Certification for an NGS Lab – the first in Mainland China.
Introduced mass spectrometry platform and expanded our multiomics service capacity.2017
Established Tianjin Sequencing Center and built a large-scale sequencing platform.
Obtained the ‘China Medical Institution’ License, the ‘China Medical Device Manufactures’ License, and ‘Laboratory Accreditation for Gene Amplification’. Grew our clinical services.
Established Novogene Corporation Inc. & Novogene (UK) Company Ltd., forming a model for our global operations.2014
Opened first sequencing center in the US at the University of California, Davis. This started the glocalization process.2016
Established Novogene (HK) Company Ltd. and started to expand overseas business.2013